Co-Founder & CEO
Profile summary: BS in Computer Science at Stanford University
Intelligencia AI
Intelligencia utilizes machine learning algorithms to provide accurate probability of success assessments for drug development, enabling pharmaceutical companies to identify and quantify risks across various therapeutic areas. By offering transparent AI-driven insights, the platform enhances decision-making and optimizes clinical trial design, ultimately increasing the likelihood of successful drug approvals.
- Artificial Intelligence
- Data & Analytics
- Biotechnology
- Software Only
Updated 13 months ago
Funding
Raised to date
$26.4MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
across 2 rounds
$16.4M · Series B
Announced Jun 2023
Disclosed cumulative: $26.4M
2/2
RoundDateAmountValuationInvestors
Founders
Product
Problem
The biopharmaceutical industry faces high costs and failure rates in drug development due to inaccurate risk assessment and inefficient clinical trial design. Traditional methods often lack transparency and struggle to integrate diverse data sources for reliable probability of success (PoS) predictions. This leads to suboptimal decision-making, wasted resources, and delays in bringing new therapies to market.
Solution
Intelligencia AI offers an AI-driven platform that provides pharmaceutical companies with transparent and accurate probability of success (PoS) assessments for drug development candidates. By leveraging machine learning algorithms and a comprehensive data ontology, the platform identifies and quantifies risks across various therapeutic areas and clinical stages. The solution delivers actionable insights into the underlying drivers of technical and regulatory risk, enabling informed decision-making and optimized clinical trial design. Intelligencia AI helps standardize risk evaluation processes, bolsters internal risk identification, and facilitates the review of the competitive landscape for strategic portfolio management.
Target Audience
The primary target audience includes pharmaceutical and biotech companies, particularly those involved in drug development, portfolio strategy, and clinical trial design.
Features
- AI-powered probability of success (PoS) predictions validated retrospectively and prospectively across all clinical development stages
- Transparent AI models that reveal the key features driving PoS predictions, addressing the "how" and "why" behind the results
- Real-time tracking of clinical programs organized by proprietary ontologies
- Expert data curation and quality control by biomedical professionals
- Visualization of the drivers of PoS predictions across hundreds of dimensions
- Integration of clinical development data, including real-world evidence, to improve prediction accuracy
- Continuous model innovation and refinement based on partner and customer feedback